AdvaMed Q4 2025: United Advocacy in a Year of Disruption
The fourth quarter capped a year of uncertainty in Washington, including a federal investigation into medtech imports and prolonged government disruption. These developments put new pressure on the industry and reinforced the need for strong, unified advocacy.
AdvaMed and its members responded quickly and decisively. In October, the association delivered a comprehensive submission to the Commerce Department, backed by member data, real-world examples, and billions of dollars in planned U.S. investment. The effort demonstrated the essential role medtech plays in patient care, economic growth, and national security.
The response was significant. More than 360 public comments supported AdvaMed’s position, warning that tariffs would disrupt patient access and the medtech supply chain.
Download the full report to see how member engagement, data, and coordinated advocacy shaped the conversation and positioned the industry for what comes next.